You are here
Award Data
The Award database is continually updated throughout the year. As a result, data for FY23 is not expected to be complete until September, 2024.
Download all SBIR.gov award data either with award abstracts (290MB)
or without award abstracts (65MB).
A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.
The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.
-
Development of Novel Therapeutic Molecules for Treatment of Squamous Head and Neck Cancers
SBC: Mekanistic Therapeutics, LLC Topic: 102Mekanistic Therapeutics seeks to design, discover, and develop anti-cancer agents that selectively inhibit multiple oncogenic pathways. Among Mekanistic’s portfolio are dual and highly selective inhibitors of EGFR and PI3 kinase, which were rationally designed to only target these two critical oncogenes. The PI3 kinase (PI3K)/AKT/mTOR pathway plays a central role in driving tumor cell survival a ...
STTR Phase I 2021 Department of Health and Human ServicesNational Institutes of Health -
General Purpose Radiation Detector Front End and Digital Processor
SBC: H3D, INC. Topic: DTRA20B002This project aims to create a general-purpose readout architecture that will allow the rapid deployment of next generation detection systems. The system will be based on the development of a programmable general-purpose integrated circuit (GPIC) that has the front-end electronics required to read out signals from a variety of radiation detectors, especially next generation scintillators and semico ...
STTR Phase I 2021 Department of DefenseDefense Threat Reduction Agency -
High-density optical tomography of cerebral blood flow and metabolism in small animals
SBC: BIOPTICS TECHNOLOGY LLC Topic: 105ABSTRACT Many clinical situations, including stroke, expose the brain to insufficient cerebral blood flow (CBF) that cannot maintain normal cerebral metabolic rate of oxygen consumption (CMRO2) requirements, thereby leading to cerebral ischemic/hypoxic stresses and neurological disorders. Effective interventions are dependent on the findings of CBF/CMRO2 improvement and eventually neural recovery. ...
STTR Phase I 2021 Department of Health and Human ServicesNational Institutes of Health -
Cerenkov Multi-Spectral Imaging (CMSI) for Adaptation and Real-Time Imaging in Radiotherapy
SBC: ENDECTRA LLC Topic: 102PROJECT SUMMARY Understanding of tumor molecular characteristics during a course of radiotherapy (RT) treatment is crucial to assess the efficacy of the treatment and adapt radiation dosage to optimize outcomes. Unfortunately, this cannot be routinely achieved by current diagnostic nuclear imaging modalities due to complex logistics and prohibitive costs. Alternatively, Cerenkov Emission (CE) is a ...
STTR Phase I 2020 Department of Health and Human ServicesNational Institutes of Health -
Developing novel RPPA for the detection of metastatic prostate cancer
SBC: TYMORA ANALYTICAL OPERATIONS LLC Topic: 102PROJECT SUMMARY Reverse phase protein arrayRPPAhas emerged as a promising antibody based highly quantitative proteomic technology suitable for profiling proteins in hundreds to thousands of patient samplesThe throughputsensitivityand cost effectiveness of RPPAtogether with its ability to deal with minuscule sample amountshave propelled applications of the technology in basicpreclinical and clinica ...
STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health -
Developing high throughput measurement of thiopurine in DNA by mass spectrometry
SBC: TYMORA ANALYTICAL OPERATIONS LLC Topic: 400PROJECT SUMMARY Thiopurines such as mercaptopurine are S-substituted antimetabolites used as functional analogs to natural nucleobase precursors. They are highly effective against hematologic malignancies (leukemia and lymphoma) and autoimmune diseases (inflammatory bowel diseases [IBD]), with an estimated patient population andgt;350,000 in the US. However, the cytotoxicity of thiopurines depends ...
STTR Phase I 2020 Department of Health and Human ServicesNational Institutes of Health -
Developing EV surface proteins as biosignatures for Alzheimer's disease (AD)
SBC: TYMORA ANALYTICAL OPERATIONS LLC Topic: NIAPROJECT SUMMARY The rising number of Americans currently living with Alzheimer’s disease (AD) demands pressing therapeutic and diagnostic solutions. The consensus is that early detection is critical to delay and better manage the disease. The recent discovery of extracellular vesicles (EVs) and their potentially important cellular functions in neuronal-glial communication, synaptic plasticity, o ...
STTR Phase I 2020 Department of Health and Human ServicesNational Institutes of Health -
Novel Nanosecond Laser and Ultrasound to Selectively Treat Eye Blood Vessels
SBC: PHOTOSONOX LLC Topic: NEIABSTRACT / PROJECT SUMMARY Wet age-related macular degeneration (AMD) is the leading cause of irreversible blindness in the developed world. Anti-VEGF therapy is currently the gold standard for wet AMD treatment. However, up to 50% of patients in the long term have a suboptimal response to anti-VEGF therapy. A better alternative method for treatment of AMD is urgently needed. We have recently inve ...
STTR Phase I 2020 Department of Health and Human ServicesNational Institutes of Health -
Photo-mediated ultrasound therapy for treatment of cutaneous vascular malformations
SBC: PHOTOSONOX LLC Topic: NIBIBABSTRACT: Cutaneous vascular malformations (CVM), such as port wine stain (PWS) which occurs in 0.3–0.5% of newborns, are often a cause of great concern to patients for both medical and cosmetic reasons. Laser irradiation with flashlamp-pumped pulsed dye lasers, i.e. photothermolysis therapy (PTT), is currently the gold standard treatment for PWS. Most patients with PWS, however, fail to clear c ...
STTR Phase I 2020 Department of Health and Human ServicesNational Institutes of Health -
Stress forces huESC differentiation; confirmation as an accurate DevTox HTS
SBC: REPRODUCTIVE STRESS MEASUREMENT MECHANISMS & MANAGEMENT CORP Topic: REXECUTIVE SUMMARY - huESC HTS2 - human Toxic stress effects in 1st trimester pregnancy leads to $10s of billions of US health care costs/year and is a significant part of the $2.5-4B/year US Developmental and Reproductive Technology (DART industry. Current DART techniques use slow, expensive pregnant rodent tests, or tests of embryonic stem cells (ESCs) that are cultured to lose “stemness” and ...
STTR Phase I 2020 Department of Health and Human ServicesNational Institutes of Health